Liver transplantation outcomes after transarterial chemotherapy for hepatocellular carcinoma.
Journal
The British journal of surgery
ISSN: 1365-2168
Titre abrégé: Br J Surg
Pays: England
ID NLM: 0372553
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
14
11
2019
revised:
05
01
2020
accepted:
27
01
2020
pubmed:
30
3
2020
medline:
23
2
2021
entrez:
30
3
2020
Statut:
ppublish
Résumé
Transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) awaiting liver transplantation is widespread, although evidence that it improves outcomes is lacking and there exist concerns about morbidity. The impact of TACE on outcomes after transplantation was evaluated in this study. Patients with HCC who had liver transplantation in the UK were identified, and stratified according to whether they received TACE between 2006 and 2016. Cox regression methods were used to estimate hazard ratios (HRs) for death and graft failure after transplantation adjusted for donor and recipient characteristics. In total, 385 of 968 patients (39·8 per cent) received TACE. Five-year patient survival after transplantation was similar in those who had or had not received TACE: 75·2 (95 per cent c.i. 68·8 to 80·5) and 75·0 (70·5 to 78·8) per cent respectively. After adjustment for donor and recipient characteristics, there were no differences in mortality (HR 0·96, 95 per cent c.i. 0·67 to 1·38; P = 0·821) or graft failure (HR 1·01, 0·73 to 1·40; P = 0·964). The number of TACE treatments (2 or more versus 1: HR 0·97, 0·61 to 1·55; P = 0·903) or the time of death after transplantation (within or after 90 days; P = 0·291) did not alter the outcome. The incidence of hepatic artery thrombosis was low in those who had or had not received TACE (1·3 and 2·4 per cent respectively; P = 0·235). TACE delivered to patients with HCC before liver transplant did not affect complications, patient death or graft failure after transplantation. La quimioembolización transarterial (transarterial chemoembolization, TACE) en pacientes con carcinoma hepatocelular (hepatocellular carcinoma, HCC) se utiliza como puente al trasplante hepático, aunque falta evidencia de que mejore los resultados y la morbilidad relacionada es motivo de preocupación. En este estudio se evaluó el impacto de la TACE en los resultados tras el trasplante para analizar las complicaciones. MÉTODOS: Se identificaron los receptores de trasplante hepático por HCC en el Reino Unido y se estratificaron según si habían recibido TACE entre 2006 y 2016. Se utilizó el método de regresión de Cox para estimar los cocientes de riesgos instantáneos (hazard ratio, HR) para la mortalidad post-trasplante y el fallo del injerto ajustados por las características del donante y del receptor. En total, 385 (39,8%) de 968 pacientes recibieron TACE, observándose similar supervivencia del paciente a los 5 años después del trasplante: 75,2% (i.c. del 95%: 68,8% a 80,5%) con TACE y 75,0% (70,5% a 78,8 %) sin TACE. Después de ajustar según las características del donante y del receptor, no hubo diferencias en la mortalidad (HR: 0,96, 0,67 a 1,38; P = 0,82) o en el fallo del injerto (HR: 1,01, 0,73 a 1,40; P = 0,96). El número de tratamientos con TACE (≥ 2 tratamientos TACE HR: 0,97, 0,61 a 1,55; P = 0,90) o el período de tiempo después del trasplante (mortalidad del paciente antes o después de 90 días; P = 0,29) no alteró el resultado. La incidencia de trombosis de la arteria hepática fue baja en aquellos que recibieron TACE o no (1,3% y 2,5%, respectivamente; P = 0,23). El fallo del injerto debido a eventos oclusivos fue similar en el grupo de pacientes que recibieron TACE (8,0% o 11/137) o que no la recibieron (6,7% o 5/75) TACE (P = 0,74). CONCLUSIÓN: La administración de TACE en pacientes con HCC antes del trasplante hepático no influyó en las complicaciones post-trasplante, la mortalidad del paciente o el fallo del injerto.
Sections du résumé
BACKGROUND
Transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) awaiting liver transplantation is widespread, although evidence that it improves outcomes is lacking and there exist concerns about morbidity. The impact of TACE on outcomes after transplantation was evaluated in this study.
METHODS
Patients with HCC who had liver transplantation in the UK were identified, and stratified according to whether they received TACE between 2006 and 2016. Cox regression methods were used to estimate hazard ratios (HRs) for death and graft failure after transplantation adjusted for donor and recipient characteristics.
RESULTS
In total, 385 of 968 patients (39·8 per cent) received TACE. Five-year patient survival after transplantation was similar in those who had or had not received TACE: 75·2 (95 per cent c.i. 68·8 to 80·5) and 75·0 (70·5 to 78·8) per cent respectively. After adjustment for donor and recipient characteristics, there were no differences in mortality (HR 0·96, 95 per cent c.i. 0·67 to 1·38; P = 0·821) or graft failure (HR 1·01, 0·73 to 1·40; P = 0·964). The number of TACE treatments (2 or more versus 1: HR 0·97, 0·61 to 1·55; P = 0·903) or the time of death after transplantation (within or after 90 days; P = 0·291) did not alter the outcome. The incidence of hepatic artery thrombosis was low in those who had or had not received TACE (1·3 and 2·4 per cent respectively; P = 0·235).
CONCLUSION
TACE delivered to patients with HCC before liver transplant did not affect complications, patient death or graft failure after transplantation.
ANTECEDENTES
La quimioembolización transarterial (transarterial chemoembolization, TACE) en pacientes con carcinoma hepatocelular (hepatocellular carcinoma, HCC) se utiliza como puente al trasplante hepático, aunque falta evidencia de que mejore los resultados y la morbilidad relacionada es motivo de preocupación. En este estudio se evaluó el impacto de la TACE en los resultados tras el trasplante para analizar las complicaciones. MÉTODOS: Se identificaron los receptores de trasplante hepático por HCC en el Reino Unido y se estratificaron según si habían recibido TACE entre 2006 y 2016. Se utilizó el método de regresión de Cox para estimar los cocientes de riesgos instantáneos (hazard ratio, HR) para la mortalidad post-trasplante y el fallo del injerto ajustados por las características del donante y del receptor.
RESULTADOS
En total, 385 (39,8%) de 968 pacientes recibieron TACE, observándose similar supervivencia del paciente a los 5 años después del trasplante: 75,2% (i.c. del 95%: 68,8% a 80,5%) con TACE y 75,0% (70,5% a 78,8 %) sin TACE. Después de ajustar según las características del donante y del receptor, no hubo diferencias en la mortalidad (HR: 0,96, 0,67 a 1,38; P = 0,82) o en el fallo del injerto (HR: 1,01, 0,73 a 1,40; P = 0,96). El número de tratamientos con TACE (≥ 2 tratamientos TACE HR: 0,97, 0,61 a 1,55; P = 0,90) o el período de tiempo después del trasplante (mortalidad del paciente antes o después de 90 días; P = 0,29) no alteró el resultado. La incidencia de trombosis de la arteria hepática fue baja en aquellos que recibieron TACE o no (1,3% y 2,5%, respectivamente; P = 0,23). El fallo del injerto debido a eventos oclusivos fue similar en el grupo de pacientes que recibieron TACE (8,0% o 11/137) o que no la recibieron (6,7% o 5/75) TACE (P = 0,74). CONCLUSIÓN: La administración de TACE en pacientes con HCC antes del trasplante hepático no influyó en las complicaciones post-trasplante, la mortalidad del paciente o el fallo del injerto.
Autres résumés
Type: Publisher
(spa)
La quimioembolización transarterial (transarterial chemoembolization, TACE) en pacientes con carcinoma hepatocelular (hepatocellular carcinoma, HCC) se utiliza como puente al trasplante hepático, aunque falta evidencia de que mejore los resultados y la morbilidad relacionada es motivo de preocupación. En este estudio se evaluó el impacto de la TACE en los resultados tras el trasplante para analizar las complicaciones. MÉTODOS: Se identificaron los receptores de trasplante hepático por HCC en el Reino Unido y se estratificaron según si habían recibido TACE entre 2006 y 2016. Se utilizó el método de regresión de Cox para estimar los cocientes de riesgos instantáneos (hazard ratio, HR) para la mortalidad post-trasplante y el fallo del injerto ajustados por las características del donante y del receptor.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1183-1191Subventions
Organisme : Department of Health
ID : DRF-2016-09-132
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S020470/1
Pays : United Kingdom
Informations de copyright
© 2020 BJS Society Ltd Published by John Wiley & Sons Ltd.
Références
Kulik L, Heimbach JK, Zaiem F, Almasri J, Prokop LJ, Wang Z et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis. Hepatology 2018; 67: 381-400.
Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 2014; 63: 844-855.
Kohla MAS, Zeid MA, Al-Warraky M, Taha H, Gish RG. Predictors of hepatic decompensation after TACE for hepatocellular carcinoma. BMJ Open Gastroenterol 2015; 2: e000032.
Boteon APCDS, Boteon YL, Vinuela EF, Derosas C, Mergental H, Isaac JR et al. The impact of transarterial chemoembolization induced complications on outcomes after liver transplantation: a propensity-matched study. Clin Transplant 2018; 32: e13255.
Sneiders D, Houwen T, Pengel LHM, Polak WG, Dor FJMF, Hartog H. Systematic review and meta-analysis of posttransplant hepatic artery and biliary complications in patients treated with transarterial chemoembolization before liver transplantation. Transplantation 2018; 102: 88-96.
Agopian VG, Harlander-Locke MP, Ruiz RM, Klintmalm GB, Senguttuvan S, Florman SS et al. Impact of pretransplant bridging locoregional therapy for patients with hepatocellular carcinoma within Milan criteria undergoing liver transplantation: analysis of 3601 patients from the US Multicenter HCC Transplant Consortium. Ann Surg 2017; 266: 525-535.
Pommergaard HC, Rostved AA, Adam R, Thygesen LC, Salizzoni M, Gómez Bravo MA et al.; European Liver and Intestine Transplant Association (ELITA). Locoregional treatments before liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry. Transpl Int 2018; 31: 531-539.
Zalewska K; Liver Advisory Group on behalf of NHSBT. Liver Transplantation: Selection Criteria and Recipient Registration: Policy Pol 195/6; 2017. http://odt.nhs.uk/pdf/liver_selection_policy.pdf [accessed 7 January 2019].
Menon KV, Hakeem AR, Heaton ND. Review article: liver transplantation for hepatocellular carcinoma - a critical appraisal of the current worldwide listing criteria. Aliment Pharmacol Ther 2014; 40: 893-902.
Zalewska K. Deceased Donor Liver Distribution and Allocation: Policy Pol 196/5; 2018. https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/9439/pol196_5-liver-allocation-policy.pdf [accessed 10 January 2019].
NHS Blood and Transplant Organ Donation and Transplantation Directorate, Liver Advisory Group. Provision of Standard Data Sets for Liver Transplant; 2015. http://odt.nhs.uk/pdf/advisory_group_papers/LAG/Provision_of_Standard_Data_Set_for_Liver_Transplant_v4.pdf [accessed 15 September 2018].
Tovikkai C, Charman SC, Praseedom RK, Gimson AE, Watson CJ, Copley LP et al. Linkage of a national clinical liver transplant database with administrative hospital data: methods and validation. Transplantation 2014; 98: 341-347.
NHS Digital. Data Access Request Service (DARS). https://digital.nhs.uk/services/data-access-request-service-dars [accessed 30 August 2018].
Jacob M, Copley LP, Lewsey JD, Gimson A, Rela M, van der Meulen JH; UK and Ireland Liver Transplant Audit. Functional status of patients before liver transplantation as a predictor of posttransplant mortality. Transplantation 2005; 80: 52-57.
Barber K, Madden S, Allen J, Collett D, Neuberger J, Gimson A; United Kingdom Liver Transplant Selection and Allocation Working Party. Elective liver transplant list mortality: development of a United Kingdom end-stage liver disease score. Transplantation 2011; 92: 469-476.
Germani G, Gurusamy K, Garcovich M, Toso C, Fede G, Hemming A et al. Which matters most: number of tumors, size of the largest tumor, or total tumor volume? Liver Transpl 2001; 17: S58-S66.
NHS Blood and Transplant Organ Donation and Transplantation Directorate, Liver Advisory Group. LAG(18)4. Update on the HCC Down-staging Service Evaluation; 2018. https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/10681/update-on-hcc-downstaging-v2.pdf [accessed 30 September 2018].
The Lancet Oncology. Measuring the quality of cancer care in UK hospitals. Lancet Oncol 2016; 17: 1171.
Charman S, Copley L, Tovikkai C, van der Meulen; Clinical Effectiveness Unit, Royal College of Surgeons of England. UK Liver Transplant Audit in Patients who Received Liver Transplant Between 1 March 1994 and 1 March 2012: Annual Report to the Advisory Group of National Specialised Services, Department of Health; 2012. www.rcseng.ac.uk/library-and-publications>non-journal-publications [accessed 12 March 2019].
White I, Royston P, Wood A. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011; 30: 377-399.
Panaro F, Ramos J, Gallix B, Mercier G, Herrero A, Niampa H et al. Hepatic artery complications following liver transplantation. Does preoperative chemoembolization impact the postoperative course? Clin Transplant 2014; 28: 598-605.
Fang ZT, Zhang W, Wang GZ, Zhou B, Yang GW, Qu XD et al. Circulating tumor cells in the central and peripheral venous compartment - assessing hematogenous dissemination after transarterial chemoembolization of hepatocellular carcinoma. Onco Targets Ther 2014; 7: 1311-1318.
Lin TS, Chiang YC, Chen CL, Concejero AM, Cheng YF, Wang CC et al. Intimal dissection of the hepatic artery following transarterial embolization for hepatocellular carcinoma: an intraoperative problem in adult living donor liver transplantation. Liver Transpl 2009; 15: 1553-1556.
Bekker J, Ploem S, de Jong KP. Early hepatic artery thrombosis after liver transplantation: a systematic review of the incidence, outcome and risk factors. Am J Transplant 2009; 9: 746-757.
O'Neill S, Roebuck A, Khoo E, Wigmore SJ, Harrison EM. A meta-analysis and meta-regression of outcomes including biliary complications in donation after cardiac death liver transplantation. Transpl Int 2014; 27: 1159-1174.
NHS Blood and Transplant Organ Donation and Transplantation Directorate, Liver Advisory Group. LAG(14)31a. Fixed Term Working Unit - Organ Allocation; 2014. http://odt.nhs.uk/pdf/advisory_group_papers/LAG/Allocation_System.pdf [accessed 30 September 2018].